| Q33957956 | Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity |
| Q37954286 | Bacterial toxins and the nervous system: neurotoxins and multipotential toxins interacting with neuronal cells |
| Q36737852 | Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury |
| Q89683175 | Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence |
| Q51472849 | Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury. |
| Q34902996 | Crucial role of TRPC1 and TRPC4 in cystitis-induced neuronal sprouting and bladder overactivity |
| Q38564108 | Current and potential urological applications of botulinum toxin A. |
| Q46716999 | Effect of basolateral adenosine triphosphate on chloride secretion by bovine oviductal epithelium |
| Q33563019 | Effect of inflammatory mediators on ATP release of human urothelial RT4 cells |
| Q40215681 | Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamide-Induced Cystitis |
| Q44276279 | Enhanced purinergic contractile responses and P2X1 receptor expression in detrusor muscle during cycles of hypoxia-glucopenia and reoxygenation |
| Q33886615 | Expression and distribution of ectonucleotidases in mouse urinary bladder |
| Q36788773 | Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y(6) activation of the phospholipase C/inositol trisphosphate pathway |
| Q37297168 | Extracellular purines are biomarkers of neutrophilic airway inflammation |
| Q37680912 | Functional TRP and ASIC-like channels in cultured urothelial cells from the rat. |
| Q40742315 | Inhibition of nitric oxide synthase prevents muscarinic and purinergic functional changes and development of cyclophosphamide-induced cystitis in the rat. |
| Q51558644 | Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. |
| Q34356086 | Local receptors as novel regulators for peripheral clock expression |
| Q42933872 | Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis |
| Q89834810 | Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders |
| Q60958347 | Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome |
| Q37978568 | Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. |
| Q35057494 | Mechanisms of disease: involvement of the urothelium in bladder dysfunction |
| Q36445282 | Mechanisms of disease: role of purinergic signaling in the pathophysiology of bladder dysfunction |
| Q35811264 | Morphology of P2X3-immunoreactive nerve endings in the rat laryngeal mucosa |
| Q34903817 | Non-neuronal acetylcholine and urinary bladder urothelium |
| Q35996597 | O'Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome |
| Q45907261 | OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. |
| Q34624931 | Overactive and underactive bladder dysfunction is reflected by alterations in urothelial ATP and NO release |
| Q42742419 | P2Y11 impairs cell proliferation by induction of cell cycle arrest and sensitizes endothelial cells to cisplatin-induced cell death |
| Q41512893 | Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder |
| Q34110591 | Pannexin 1 channels play essential roles in urothelial mechanotransduction and intercellular signaling |
| Q42027313 | Peripheral and central P2X receptor contributions to colon mechanosensitivity and hypersensitivity in the mouse |
| Q85048835 | Pharmacological modulation of the micturition pattern in normal and cyclophosphamide pre-treated conscious rats |
| Q36270494 | Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis |
| Q98292017 | Purinergic P2X7 receptors as therapeutic targets in interstitial cystitis/bladder pain syndrome; key role of ATP signaling in inflammation |
| Q42367885 | Purinergic Signalling: Therapeutic Developments |
| Q37463074 | Purinergic mechanosensory transduction and visceral pain |
| Q91151841 | Purinergic receptor mediated calcium signalling in urothelial cells |
| Q38061933 | Purinergic signalling in the lower urinary tract |
| Q37620260 | Purinergic signalling in the urinary tract in health and disease |
| Q54205799 | Purinergic signalling underlies transforming growth factor-β-mediated bladder afferent nerve hyperexcitability. |
| Q35545723 | Purinoceptors as therapeutic targets for lower urinary tract dysfunction |
| Q37365680 | Receptor activated bladder and spinal ATP release in neurally intact and chronic spinal cord injured rats |
| Q53655799 | Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. |
| Q52340820 | Role of neurogenic inflammation in local communication in the visceral mucosa. |
| Q50144688 | Safety and Feasibility of Intravesical Instillation of Botulinum Toxin-A in Hydrogel-Based Slow Release Delivery System in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Pilot Study |
| Q33936146 | Sensitization of pelvic afferent nerves in the in vitro rat urinary bladder-pelvic nerve preparation by purinergic agonists and cyclophosphamide pretreatment |
| Q34080499 | Signalling molecules in the urothelium |
| Q33972580 | Spontaneous contractions evoke afferent nerve firing in mouse bladders with detrusor overactivity |
| Q58895010 | Subcutaneous Botulinum Toxin for Chronic Post-Thoracotomy Pain |
| Q38115266 | Targets for botulinum toxin in the lower urinary tract |
| Q34528370 | The Role of the Mucosa in Normal and Abnormal Bladder Function |
| Q59121222 | The effects of tempol on cyclophosphamide-induced oxidative stress in rat micturition reflexes |
| Q36898688 | The uroepithelial-associated sensory web. |
| Q46965277 | Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. |
| Q97884829 | Therapeutic use of botulinum toxin in pain treatment |
| Q34760718 | Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome |
| Q42422183 | Urothelial ATP exocytosis: regulation of bladder compliance in the urine storage phase |
| Q84375630 | Urothelial signaling |